DELRAY BEACH, Fla., March 6, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Chemiluminescence Immunoassay Market is projected to grow from about USD 11.58 billion in 2026 to USD 16.39 billion by 2031, at a CAGR of 7.2%.
Browse through 380 market data tables and 65 figures spread across 400 pages and the in-depth TOC on the "Chemiluminescence immunoassays market - Global Forecast to 2031"
Chemiluminescence Immunoassay Market Size & Forecast:
Chemiluminescence Immunoassay Market Trends & Insights:
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131865271
The CLIA market demonstrates its growth through the increasing global incidence of chronic and infectious diseases, which include cancer, cardiovascular disorders, thyroid diseases, and viral infections that require highly accurate and dependable diagnostic tests. The rising emphasis on early disease detection and preventive healthcare drives CLIA adoption because it provides better testing results through its advanced sensitivity, wide testing range, and capacity to find minute biological indicators. Laboratory operations achieve better performance because technological advancements deliver fully automated, high-throughput analyzers, improved reagent stability, and enhanced multiplex testing capabilities. The market expansion receives additional support through three factors, which include emerging markets building new healthcare facilities, expanding diagnostic laboratory networks, and increasing healthcare spending. The demand for CLIA systems in hospital and reference laboratory settings worldwide continues to grow because of two factors, which include the rising use of biomarker-based testing in personalized medicine and pharmaceutical research and clinical trials, and the strict blood screening standards and the public's increased knowledge of routine health checkups.
By product, the consumables segment is expected to grow at the highest CAGR during the forecast period.
The consumables segment is experiencing strong growth because diagnostic testing needs require constant and high-volume consumption of reagents and other essential materials, which include calibrators and controls, wash solutions, and reaction cuvettes. The need for assay kits and reagent packs in hospitals and reference laboratories has increased because test volumes for infectious diseases, cancer biomarkers, cardiac markers, endocrine disorders, and therapeutic drug monitoring have risen. The market experiences regular revenue generation through consumables because they need to be restocked, which leads to ongoing business growth. Laboratory efficiency improves through enhancements in reagent stability and ready-to-use formulations, extended product shelf life, and enhanced quality controls, which result in less waste and increased user adoption. The global consumption of CLIA reagents and related supplies continues to rise because automated high-throughput CLIA systems need more testing capabilities, and as preventive health screening programs expand, blood safety testing requirements grow.
Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=131865271
By sample type, the saliva segment is expected to grow at the highest CAGR during the forecast period.
The growth of the saliva sample type segment is driven by the increasing demand for non-invasive, patient-friendly diagnostic methods that improve comfort and compliance compared to blood collection. Saliva testing eliminates the requirement for certified phlebotomists while it decreases infection dangers and allows users to gather samples easily at hospitals, their homes, and during public health testing events. The development of better assay sensitivity, together with improved biomarker detection technologies, has made saliva testing more trustworthy for its use in hormone assessment (such as cortisol monitoring), infectious disease testing, and drug detection and evaluation of stress and metabolic functions. The growing use of remote healthcare services, including telemedicine and decentralized testing systems, is driving demand for saliva sample collection methods.
By end user, the saliva segment is expected to grow at the highest CAGR during the forecast period.
The chemiluminescence immunoassay (CLIA) market is growing in the hospital segment because hospitals require efficient testing solutions that deliver precise results to facilitate quick medical decisions, ultimately leading to better patient outcomes. Hospitals require dependable tests to assess cardiac markers, sepsis indicators, cancer biomarkers, hormones, and infectious pathogens because they treat numerous patients with chronic diseases and infectious diseases. The CLIA system enables emergency departments, intensive care units, and inpatient services to start immediate medical treatment through its enhanced sensitivity, extensive test options, and quick result delivery. The implementation of centralized hospital laboratories together with automated diagnostic systems establishes efficient work processes while diminishing manual mistakes and producing uniform test outcomes.
North America dominates the global chemiluminescence immunoassays market in 2025.
The chemiluminescence immunoassay market in North America is growing as hospitals and reference laboratories in the region adopt automated diagnostic technologies, and the region has advanced healthcare systems and spends heavily on healthcare services. The region requires advanced biomarker detection technologies that can identify markers of various chronic and infectious diseases, including cancer and cardiovascular disorders, and endocrine conditions. These tests receive broad usage because strong reimbursement systems, helpful regulatory processes, and regular test approvals enable medical facilities to perform testing outside traditional laboratory settings. The combination of strong research and development funding, major diagnostic companies operating in the market, and ongoing advancements, which include laboratory automation, artificial intelligence development, and the introduction of new testing methods, will lead to laboratory testing process improvements and more accurate diagnostic results.
Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=131865271
Top Companies in Chemiluminescence Immunoassay Market:
The Top Companies in Chemiluminescence Immunoassay Market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), DiaSorin S.p.A. (Italy), Tosoh Corporation (Japan), Werfen (Spain), Bio-Rad Laboratories, Inc. (US), Shenzhen Mindray Biomedical Electronics Co., Ltd. (China), Fujirebio (Japan), Autobio Diagnostics Co., Ltd. (China), Artron Laboratories Inc. (Canada), Abnova Corporation (Taiwan), and Elabscience (China).
Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting
Related Reports:
Infectious Disease Diagnostics Market - Global Forecast to 2030
Interventional Oncology Market - Global Forecast to 2029
Immunoassay Market - Global Forecast to 2030
Life Science Instrumentation Market - Global Forecast to 2031
Medical Robots Market - Global Forecast to 2029
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/chemiluminescence-immunoassay-market-worth-16-39-billion-by-2031--marketsandmarkets-302706511.html
Zalando hat 2025 kräftig zugelegt und seine eigenen Ziele am oberen Ende der Spannen erreicht. Der Umsatz des im DAX notierten Online-Modehändlers stieg um 16,8 Prozent auf 12,35 Milliarden Euro und lag damit leicht über den Markterwartungen. Das Bruttowarenvolumen (GMV) kletterte um 14,7 Prozent auf 17,56 Milliarden Euro. Rückenwind bekam das Geschäft vor allem durch die Übernahme des Konkurrenten About You sowie den verstärkten Einsatz Künstlicher Intelligenz in Vertrieb und Plattformsteuerung.
Operativ verbesserte sich Zalando ebenfalls: Das bereinigte Ergebnis vor Zinsen und Steuern (EBIT) erhöhte sich auf 591 Millionen Euro nach 511 Millionen Euro im Vorjahr, die Marge blieb mit 4,8 Prozent stabil und leicht über den Analystenprognosen. Unter dem Strich sank der Gewinn jedoch auf 213 Millionen Euro von zuvor 251 Millionen Euro und verfehlte damit die Erwartungen. Für das laufende Jahr stellt das Management ein weiteres Wachstum von 12 bis 17 Prozent bei GMV und Umsatz in Aussicht; das bereinigte EBIT soll auf 660 bis 740 Millionen Euro steigen. Die mittelfristigen Ziele bis 2028 – jährliche Zuwächse von 8 bis 13 Prozent bei Umsatz und GMV sowie eine EBIT-Marge von 6 bis 8 Prozent – wurden bestätigt, die angepeilten jährlichen Synergien aus der About-You-Übernahme von 100 Millionen Euro sollen bereits 2028 und damit ein Jahr früher erreicht sein.
An der Börse sorgte vor allem die Kapitalmarktpolitik für Auftrieb. Der Konzern kündigte ein Aktienrückkaufprogramm von bis zu 300 Millionen Euro an, das bis Ende Juli laufen soll. Die Aktie legte im Tagesverlauf zweistellig zu und notierte zeitweise rund elf Prozent höher bei 22,35 Euro. Damit reagierte der Markt positiv auf die Kombination aus besser als erwarteten operativen Kennzahlen, bestätigtem Wachstumskurs und der Ankündigung, überschüssiges Kapital an die Anteilseigner zurückzuführen – obwohl die Zalando-Papiere seit Jahresbeginn deutlich im Minus liegen und in den vergangenen zwölf Monaten rund ein Drittel an Wert verloren haben. Analysten hoben neben dem Rückkauf insbesondere die Rolle von KI und das Konzept des sogenannten Agentic Commerce als nächste Entwicklungsstufe des Onlinehandels hervor.
Überschattet werden die guten Zahlen von strukturellen Einschnitten im Logistiknetz. Im Zuge der Integration von About You will Zalando vier Logistikzentren in Europa schließen, darunter den Standort Erfurt mit rund 2.700 Beschäftigten. Co-Chef David Schröter sprach von einer der schwersten, zugleich aber notwendigen Entscheidungen, um die Kapazitäten an den künftigen Wachstumsbedarf anzupassen. Das Unternehmen verhandelt nach eigenen Angaben mit dem Betriebsrat über einen Sozialplan, bietet Versetzungen an andere Standorte an und arbeitet mit der örtlichen Arbeitsagentur zusammen. Weitere Maßnahmen über die bereits angekündigten Schließungen hinaus soll es dem Management zufolge nicht geben; aus der Thüringer Landespolitik kommt dennoch Kritik an der Entscheidung.
